This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon

Weight management

Orforglipron

An oral non-peptide GLP-1 agent that, unlike oral semaglutide, needs no sensitive intake rule.

1 min read 1 sources Titration Updated May 2026
Class
GLP-1 agonist (small molecule, oral)
Use
Oral (in mg/day)
Half-life
long (dosed daily)
WADA
not specifically listed

Getting started

Typical dosing (research context)

Per-day figures in mg. Orforglipron is a non-peptide small molecule, so less sensitive to intake than oral semaglutide.

Members only

Dosing recommendations are visible to logged-in members only. Logging in is free.

Log in / sign up

What is Orforglipron?

Orforglipron is an oral GLP-1 receptor agonist, but unlike semaglutide not a peptide but a small molecule. That is the key difference: small molecules survive the stomach better and do not need the strict fasting rule like oral semaglutide.

How it works

Orforglipron activates the same GLP-1 receptor as the GLP-1 peptides: more satiety, dampened appetite, better blood sugar control. Because it is a small molecule, absorption is more robust and intake more practical for everyday use.

How to take it

Oral, once daily. Unlike oral semaglutide, absorption is less sensitive, a strict fasting rule is not needed.

  • With some water, with or without food per instructions.
  • Once daily is enough given the long duration.

Dosing

Members only

Dosing recommendations are visible to logged-in members only. Logging in is free.

Log in / sign up

What the research shows

A phase 3 study (NEJM, 2025) tested orforglipron in early type 2 diabetes over 40 weeks: all three doses lowered long-term blood sugar markedly more than placebo. That makes orforglipron one of the most advanced oral GLP-1 agents with solid data.

Side effects

  • Mainly gastrointestinal: nausea, fullness, constipation or diarrhea, especially when dosing up.
  • A slow ease-in keeps this small.

Storage

Store dry, cool and protected from light, out of reach of children. Keep the original container closed and mind the expiry date.

Evidence

Sources

  1. 1 Orforglipron, an oral small-molecule GLP-1 agonist, in early type 2 diabetes (phase 3). NEJM, 2025

Keep reading

More in the lexicon

In the shop

Orforglipron in the catalog

Sizes, prices and availability for research use. Straight from the lexicon to the product page.

View in shop